Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure

被引：20

作者：

Nathwani, Nitya ^{[1
]}

Krishnan, Amrita Y. ^{[1
]}

Huang, Qin ^{[2
]}

Kim, Young ^{[2
]}

Karanes, Chatchada ^{[1
]}

Smith, Eileen P. ^{[1
]}

Forman, Stephen J. ^{[1
]}

Sievers, Eric ^{[3
]}

Thomas, Sandra H. ^{[1
]}

Chen, Robert W. ^{[1
]}

机构：

[1] City Hope Natl Med Ctr, Dept Hematol HCT, Duarte, CA 91010 USA

[2] City Hope Natl Med Ctr, Dept Pathol, Duarte, CA 91010 USA

[3] Seattle Genet, Bothell, WA USA

来源：

LEUKEMIA & LYMPHOMA | 2012年 / 53卷 / 10期

关键词：

STEM-CELL TRANSPLANTATION; DISEASE; TUBULIN; TRIAL;

D O I：

10.3109/10428194.2012.666543

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2051 / 2053

页数：3

共 50 条

[41] Complete Remissions Observed in a Subset of Pediatric Patients With CD30-expressing Malignant Lymphomas Treated in Clinical Studies of Brentuximab Vedotin (SGN-35)
Fanale, M.
Franklin, A.
Radhakrishnan, R.
Termuhlen, A.
Gopal, A. K.
Shustov, A.
Kennedy, D. A.
Sievers, E. L.
EUROPEAN JOURNAL OF CANCER, 2011, 47 : S640 - S640
[42] Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma
Foyil, Kelley V.
Kennedy, Dana A.
Grove, Laurie E.
Bartlett, Nancy L.
Cashen, Amanda F.
LEUKEMIA & LYMPHOMA, 2012, 53 (03) : 506 - 507
[43] Resolution of malignant cutaneous lesions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma
Advani, Ranjana
Pro, Barbara
Kennedy, Dana
Fanale, Michelle
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB4 - AB4
[44] Loss of CD30 Expression in Anaplastic Large Cell Lymphoma Following Brentuximab Therapy
Nielson, Colton
Fischer, Ryan
Fraga, Garth
Aires, Daniel
JOURNAL OF DRUGS IN DERMATOLOGY, 2016, 15 (07) : 894 - 895
[45] CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma
Bhatt, Shruti
Ashlock, Brittany M.
Natkunam, Yasodha
Sujoy, Victoria
Chapman, Jennifer Rose
Ramos, Juan Carlos
Mesri, Enrique A.
Lossos, Izidore S.
BLOOD, 2013, 122 (07) : 1233 - 1242
[46] Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Pro, Barbara
Advani, Ranjana
Brice, Pauline
Bartlett, Nancy L.
Rosenblatt, Joseph D.
Illidge, Tim
Matous, Jeffrey
Ramchandren, Radhakrishnan
Fanale, Michelle
Connors, Joseph M.
Yang, Yin
Sievers, Eric L.
Kennedy, Dana A.
Shustov, Andrei
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (18) : 2190 - 2196
[47] Frontline Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin and Prednisone in Patients with Peripheral T-Cell Lymphoma with Less Than 10% CD30 Expression (SGN35-032, Trial in Progress)
Jagadeesh, Deepa
Knowles, Scott
Horwitz, Steven M.
BLOOD, 2021, 138
[48] BRENTUXIMAB VEDOTIN FOR THE TREATMENT OF HODGKIN LYMPHOMA AND CD30+NON HODGKIN LYMPHOMA: A MULTICENTER TUSCANY EXPERIENCE OUTSIDE CLINICAL TRIAL
Mannelli, L.
Cecconi, N.
Iovino, L.
Galimberti, S.
Puccini, B.
Fabbri, A.
Cencini, E.
Kovalchuk, S.
Occhini, U.
Della Seta, R.
Stefanelli, A.
Birtolo, S.
Bernardeschi, P.
Riccioni, R.
Petrini, M.
Bosi, A.
Rigacci, L.
HAEMATOLOGICA, 2017, 102 : 106 - 106
[49] Preclinical and Clinical Binding Properties, Internalization Kinetics, and Clinicopathological Activity of Brentuximab Vedotin (SGN-35): Novel Antibody Drug Conjugate for Anaplastic Large Cell Lymphoma and Classical Hodgkin Lymphoma.
Fromm, Jonathan R.
McEarchern, Julie A.
Kennedy, Dana
Anju, Thomas
Shustov, Andrei R.
Gopal, Ajay K.
BLOOD, 2010, 116 (21) : 746 - 747
[50] COMPLETE RESPONSE WITH BRENTUXIMAB IN A PATIENT WITH PRIMARY REFRACTORY CD30 POSITIVE HODGKIN LYMPHOMA
Akyuz, C.
Aydin, B.
Sen, H.
Ozkutlu, S.
Yildirim, S. Ocak
Gucer, S.
Yalcin, B.
Varan, A.
Kutluk, T.
Buyukpamukcu, M.
PEDIATRIC BLOOD & CANCER, 2013, 60 : 198 - 199

← 1 2 3 4 5 →